Today, thanks to technology, it is possible to keep blood sugar under control and autonomously modulate the administration of basal insulin
Having a device that constantly monitors blood sugar and in the meantime "takes care" of regulating the administration of insulin, which is necessary to counteract the increases in blood sugar, even when perhaps a "tear" is made. It sounds like a dream, but today technology can also offer such an answer. The brand new MiniMed 780G device proves it, a sort of "new frontier" for the management of type 1 diabetes: it is an "advanced hybrid closed loop" system, capable of automating the administration of both basal insulin and boluses for correction of glycemic elevations every five minutes, in patients aged 7 to 80 with type 1 diabetes.
An important step forward
The device, developed by Medtronic, was created to further facilitate the life of those who face this disease because it reduces the effort required to manage the therapy and do it in a more peaceful way, keeping blood sugar under control more easily by intervening autonomously on the supply to compensate for inaccuracies in estimating carbohydrates and automatically correcting high blood sugar levels. In practice, it autonomously modulates the administration of both basal insulin and boluses for the correction of blood sugar rises and can even be connected to a smartphone, with obvious repercussions both on management and on the possible sending of data to the treating specialist. This is a fundamental "trump" in this phase of the pandemic, which allows greater control, in real time, of the glycemic trend by the doctor and family members, validated by scientific evidence. "All this is ensured by connectivity, the availability of constantly updated data and analysis, and the ability to instruct remote use on certified, dedicated virtual platforms – as explained by Luigi Morgese, director of the Diabetes Division at Medtronic."
Therapy is tailor-made
The availability of this device allows you to customize the therapeutic goal of blood glucose control starting from a sensor glucose value of 100 milligrams per deciliter. In short: it is an extra help for those who every day have to face the challenge with type 1 diabetes, a pathology that really changes life and requires for the whole existence to manage in an optimal way the blood sugar peaks, maintaining the values within levels recommended by the diabetologist. For those living with type 1 diabetes, in fact, it becomes a daily challenge to have to accurately calculate the amount of carbohydrates in each meal in order to determine the correct amount of bolus insulin.
And technology can really help. "MiniMed 780G is a further step towards the so-called 'closed loop system', advanced integrated" – comments Professor Dario Pitocco, Head of the Diabetology Departmental Operational Unit, Agostino Gemelli IRCCS University Hospital Foundation and Associate Professor of Endocrinology at the Catholic University of Sacred Heart. "The purpose of the device is to make the glycemic trend, over 24 hours, as stable as possible, with the achievement of a very high percentage of the" time in range ", ie the percentage of time that the patient spends at within the optimal blood glucose range. With the continuous monitoring of blood glucose, the therapeutic objectives in the management of diabetes have changed: with the achievement of a high percentage of time in range – at least 70 percent – it becomes a fundamental goal to make the quality of life of the patient with diabetes of type 1 best possible ".
According to the 2017 data of the World Diabetes Federation, in the world there are 425 million people living with diabetes (1 in 11 adults) and 212 million (1 in 2 adults) do not know they have it. In Italy, Istat estimates that in 2016 there were over 3 million and 200 thousand people with diabetes, that is 5.3 percent of the entire population. on average, nearly one in ten people have type 1 diabetes.